NL-OMON43019WithdrawnPhase 4
A randomized, multicenter Study to evaluate the Effect of secukinumab 300 mg s.c. administered during 52 Weeks to patients suffering from new-onset moderate to severe plaque Psoriasis as early Intervention compared to standard treatment with narrow band UVB (STEPin study) - STEPin
TFS Trial Form Support BV0 sites20 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Withdrawn
- Sponsor
- Enrollment
- 20
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •* Aged 18 to 40 years inclusive
- •* moderate to severe plaque psoriasis with either new onset or lasting for at least 5 years.
- •Additional inclusion criteria may apply , please refer to the protocol.
Exclusion Criteria
- •* Forms of psoriasis other than plaque-type (e.g., pustular, erythrodermic, guttate, light sensitive, drug induced) ;* Ongoing use of prohibited treatments;* Pregnant or nursing (lactating) women ;* Women of child-bearing potential not willing to use contraception;*Active ongoing inflammatory diseases other than psoriasis or psoriatic arthritis that might confound the evaluation of the benefit of secukinumab therapy ;Additional exclusion criteria may apply , please refer to the protocol.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Study of the efficacy of early intervention with secukinumab 300 mg s.c. compared to narrow-band UVB in patients with new-onset moderate to severe plaque psoriasisPlaque psoriasisEUCTR2015-002423-26-SEovartis Pharma Services AG196
Active, not recruiting
Phase 1
Study of the efficacy of early intervention with secukinumab 300 mg s.c. compared to narrow-band UVB in patients with new-onset moderate to severe plaque psoriasisPlaque psoriasisMedDRA version: 20.0Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 100000004858EUCTR2015-002423-26-EEovartis Pharma Services AG196
Active, not recruiting
Phase 1
Study of the efficacy of early intervention with secukinumab 300 mg s.c. compared to narrow-band UVB in patients with new-onset moderate to severe plaque psoriasisPlaque psoriasisMedDRA version: 20.0Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 100000004858EUCTR2015-002423-26-FIovartis Pharma Services AG196
Active, not recruiting
Phase 1
Study of the efficacy of early intervention with secukinumab 300 mg s.c. compared to narrow-band UVB in patients with new-onset moderate to severe plaque psoriasisMedDRA version: 20.0Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 100000018190Plaque psoriasisEUCTR2015-002423-26-HUovartis Pharma Services AG196
Active, not recruiting
Phase 1
Study of the efficacy of early intervention with secukinumab 300 mg s.c. compared to narrow-band UVB in patients with new-onset moderate to severe plaque psoriasisPlaque psoriasisMedDRA version: 20.0Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 100000004858EUCTR2015-002423-26-BGovartis Pharma Services AG196